The FDA has granted Takeda Pharmaceuticals approval for its type 2 diabetes drug alogliptin as a standalone medication and as an add-on to metformin in the company's Kazano formulation and with pioglitazone under the name Oseni. Alogliptin alone will be branded as Nesina.
Takeda gains FDA OK for 3 formulations of type 2 diabetes drug
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Director of Clinical Research||
Regenesis Biomedical, Inc.